

Tyczyński P, Kukuła K, Kądziela J, et al. Cardiovascular profile of patients with unilateral four renal arteries. A systematic study. Kardiol Pol. 2022.


Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.



**Figure S1.** Computed tomography (**A**–**C**). **A.** Right kidney with four renal arteries and left kidney with one renal artery. **B.** Right kidney with four renal arteries and left kidney with two renal arteries. **D.** Both kidneys with four renal arteries. **E.** Scheme presenting consecutive patients (1–11), along with the number of their renal arteries



**Figure S2.** Chart presenting paired profiles (four renal arteries for the kidney versus one/two renal arteries for the opposite kidney) of the mean ostial lumen diameter (**A**) or mean ostial lumen area (**B**) of renal arteries for consecutive nine patients (two of eleven patients had four renal arteries for both kidneys, and were excluded from this chart)



**Figure S3.** Profiles of ostial lumen diameter (**A**) or ostial lumen area (**B**) of renal arteries of kidneys with four renal arteries (11 patients)

**Table S1.** Comparison of cardiovascular profile of patients with (at least) unilateral four renal arteries and matched cohort (1:3, by sex and age) with (at least) unilateral two renal arteries

Group 1	Group 2	Relative risk	<i>P</i> -value
( <b>n</b> = 11)	(n = 33)	(95% CI)	

	(0,0) ( $(5,0,70)$ )	(1,0)(5,0,70)		1.00
Age, median (IQR)	60.0 (56–72)	61.0 (56–72)	—	1.00
At the CT diagnosis,	53.0 (42–70)	52.0 (48–65)	—	0.88
median (IQR)				
Male, n (%)	9 (81.8)	27 (81.8)	—	1.00
HTN, n (%)	10 (90.9)	26 (78.8)	1.2 (0.9–1.5)	0.66
Resistant HTN, n (%)	4 (36.4)	4 (12.1)	3.0 (0.9–10.0)	0.09 <sup>1</sup>
DM, n (%)	4 (36.4)	7 (21.2)	1.7 (0.6–4.8)	0.42
HF, n (%)	2 (18.2)	2 (6.1)	3.0 (0.4–18.8)	0.26
HL, n (%)	8 (72.7)	18 (54.5)	1.3 (0.8–2.1)	0.48
AF, n (%)	2 (18.2)	6 (18.2)	1.0 (0.2–4.3)	1.00
CAD, n (%)	4 (36.4)	8 (24.2)	1.5 (0.6–4.0)	0.46
AMI, n (%)	3 (27.3)	2 (6.1)	4.5 (0.9–23.5)	$0.09^{2}$
PCI, n (%)	2 (18.2)	6 (18.2)	1.0 (0.2–4.3)	1.00
<b>CABG, n (%)</b>	2 (18.2)	2 (6.1)	3.0 (0.5–18.8)	0.26
CAS, n (%)	1 (9.1)	0	NA	0.25
Stroke, n (%)	0	1 (3.0)	NA	1.00
LVEF, median (IQR)	63.5 (60–65)	64.0 (60–70)	$0.98 (0.41 - 2.38)^3$	0.90
e-GFR, mL/min./1.73	71.7 (17.9)	67.2 (17.2)	$0.76(0.31 - 1.83)^4$	0.48
m <sup>2</sup> , mean (SD)				
Glucose, mg/dl, me-	103 (93–118)	105 (95–118)	$0.77 (0.25 - 2.37)^5$	0.83
dian (IQR)				
TC, mg/dl, mean (SD)	166 (42)	181 (44.3)	$0.60 (0.21 - 1.75)^6$	0.38
LDL, mg/dl, mean	90.7 (42.9)	93.8 (37.6)	$0.85 (0.28 - 2.59)^7$	0.84
(SD)				
Medication	n = 10	n = 27		
ASA, n (%)	3 (30.0)	11 (40.7)	0.70 (0.22–2.29)	0.71
ACE–I, n (%)	4 (40.0)	11 (40.7)	0.98 (0.33–2.88)	1.00
ARB, n (%)	5 (50.0)	9 (33.3)	1.64 (0.58–4.68)	0.454
MRA, n (%)	8 (80.0)	19 (70.4)	1.48 (0.38–5.82)	0.694
<b>BB</b> , n (%)	9 (90.0)	19 (70.4)	2.89 (0.42–19.82)	0.39
Statin, n (%)	9 (90.0)	16 (59.3)	4.32 (0.62–30.3)	0.12
Diuretic, n (%)	4 (40.0)	9 (33.3)	1.23 (0.42–3.59)	0.72
Anticoagulant, n (%)	7 (70.0)	23 (85.2)	0.54 (0.19–1.59)	0.36

Insulin, n (%)	5 (50.0)	1 (3.7)	5.17 (2.14–12.44)	0.003
<b>OHA, n (%)</b>	8 (80.0)	6 (22.2)	6.57 (1.62–26.6)	0.002

<sup>1</sup>The power of the test: 45%. <sup>2</sup>The power of the test: 49%. <sup>3</sup>RR for LVF <60. <sup>4</sup>RR for e-GHR <60. <sup>5</sup>RR for glucose >99. <sup>6</sup>RR for TC >155. <sup>7</sup>RR for LDL >100

Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BB,  $\beta$ -blocker; CABG, coronary artery by-pass grafting; CAD, coronary artery disease; CAS, carotid artery stenosis; CT, computed tomography; DM, diabetes mellitus; HL, hyperlipidemia; HF, heart failure; HTN, arterial hypertension; IQR, interquartile range; LDL, low density lipoprotein; MRA, mineralocorticoid receptor antagonist; OHA, oral hypoglycemic agent; PCI, per-cutaneous coronary intervention; SD, standard deviation; TC, total cholesterol

	Total kidney	Right kidney	Left kidney	<i>P</i> -value		
	(n = 22)	(n = 11)	( <b>n</b> = 11)			
Kidney dimensions						
Length, mm, mean (SD)	116.8 (9.1)	117.1 (5.4)	116.6 (12.0)	0.887		
Volume, cm <sup>3</sup> , mean (SD)	186.2 (29.5)	186.9 (31.1)	183.9 (30.0)	0.941		
Thickness of the paren-	19.5 (3.4)	19.4 (3.7)	19.6 (3.3)	0.825		
chyma, mm, mean (SD)						
Number of renal arteries originating from kidney						
1 RA, n (%)	3 (13.6)	2 (18.2)	1 (9.1)	0.950		
2 RA, n (%)	6 (27.3)	3 (27.3)	3 (27.3)			
3 RA, n (%)	0 (0)	0 (0)	0 (0)			
4 RA, n (%)	13 (59.1)	6 (54.5)	7 (63.6)			

Table S2. Comparison between left and right kidney. Dimensions and number of renal arteries

Abbreviation: SD, standard deviation

**Table S3.** Dimensions of the renal arteries and comparison between four renal arteries vs. one or two renal arteries

Measurements of RA Total H	A The number of RA	
----------------------------	--------------------	--

		(n = 67)	originating from kidney		<i>P</i> -
			<b>Unilateral 4</b>	Unilateral 1 or 2	value
			(n = 52)	(n = 15)	
Mean dia	meter, mm			1	1
A	at the ostium,	3.6 (1.4)	3.3 (1.1)	4.8 (1.7)	0.005
n	nean (SD)				
A	at the narrowest	3.1 (1.1)	2.8 (0.9)	4.0 (1.4)	0.005
p	oint, mean (SD)				
Lumen ar	rea, mm <sup>2</sup>			1	
A	at the ostium, me-	10 (5.1-14.9)	7.5 (4.7-11.8)	17.1 (10.9-29.1)	0.003
d	ian (IQR)				
A	at the narrowest	7.0 (3.4-10.5)	6.6 (3.3-8.6)	11.6 (7.3-18.7)	0.027
p	oint, median				
(1	IQR)				
Distance	from the RA os-	48.3 (17.0)	51.1 (15.7)	38.4 (18.0)	0.009
tium to bi	furcation, mm,				
mean (SD	))				

Abbreviations: IQR, interquartile range; RA, renal artery; SD, standard deviation